EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis

Maddalena Napolitano, Luciano Foggia, Cataldo Patruno, Lucia Gallo, Nello Tommasino iD, Daniele Cecere, Matteo Megna

Clinical and Experimental Dermatology · 2024

DOI: 10.1093/ced/llae162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Maddalena Napolitano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors, Severity of Illness Index, Psoriasis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a common inflammatory skin disease with multiple clinical manifestations. Among AD phenotypes, psoriasiform AD shows the coexistence of eczematous itching lesions in flexural areas with psoriasiform plaques. The use of anti-interleukin (IL)-4 and anti-IL-13 in psoriasiform AD may lead to therapeutic failure or worsening of manifestations. A recent Delphi consensus proposed Janus kinase inhibitors (JAKi) as a viable alternative, even as a first-line treatment, in patients with different clinical phenotypes of AD, including psoriasiform AD. We performed a retrospective analysis of patients in our dermatology clinic with moderate-to-severe AD who were treated with JAKi. Among 192 patients overall, 21 had psoriasiform AD. We used the Eczema Area and Severity Index (EASI), Pruritus-Numerical Rating Scale and Dermatology Life Quality Index for considering severity scores, and reduction was observed in all 21 patients at week (W) 4, W16 and W24 of treatment. At W16, 81% and 67% achieved EASI-75 and EASI-90, respectively, while at W24 95% of patients achieved EASI-75 and 86% obtained EASI-90. No adverse event led to treatment interruption. This study confirmed the clinical effectiveness of JAKi treatment in adult patients with moderate-to-severe psoriasiform AD, with a good safety profile. These drugs are proposed as the first choice for treating this form of AD, although further studies with larger cohorts are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicJanus Kinase InhibitorsSeverity of Illness IndexPsoriasisHumansRetrospective StudiesMaleFemaleAdultMiddle AgedTreatment OutcomePyrimidinesYoung AdultQuality of LifePyrazolesPruritusPiperidinesNitrilesAged

Substanzen

Janus Kinase InhibitorsPyrimidinesPyrazolestofacitinibPiperidinesNitriles

Autor:innen und Institutionen

  • Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Department of Health Sciences, University of Catanzaro 'Magna Graecia', Catanzaro, Italy.

ORCID-Profile: Nello Tommasino

Zitieren

APA

Napolitano, M., Foggia, L., Patruno, C., Gallo, L., Tommasino, N., Cecere, D., & Megna, M. (2024). Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae162

Vancouver

Napolitano M, Foggia L, Patruno C, Gallo L, Tommasino N, Cecere D, et al. Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae162

BibTeX
@article{Napolitano2024,
  author = {Napolitano, Maddalena and Foggia, Luciano and Patruno, Cataldo and Gallo, Lucia and Tommasino, Nello and Cecere, Daniele and Megna, Matteo},
  title = {Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis},
  journal = {Clinical and Experimental Dermatology},
  year = {2024},
  doi = {10.1093/ced/llae162}
}
Kostenlos starten →